La Tierra está constantemente expuesta a una serie de fenómenos cósmicos que pueden tener un impacto significativo en nuestra vida cotidiana. Entre estos eventos, las tormentas solares se destacan como poderosos recordatorios de la complejidad de nuestra relación con el s …
¿Está la humanidad preparada para la próxima gran tormenta solar? Read More »
La búsqueda de una vida más saludable ha llevado a muchas personas a adoptar hábitos nutricionales que incluyen la suplementación de vitaminas. Sin embargo, existe un lado menos conocido y potencialmente riesgoso: las sobredosis vitamínicas. 1. La Fiebre d …
Sosei Group Corporation announces that PIVLAZ™ 150 mg has received marketing approval from the Ministry of Food and Drug Safety in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing.
Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.
Ipsen and GENFIT announced that the U.S. Food and Drug Administration has accepted the New Drug Application for investigational elafibranor.
Hansa Biopharma, “Hansa”, announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.
Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index.
Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.
ZyVersa Therapeutics, Inc. announced the pricing of a “reasonable best efforts” public offering of 4,000,000 shares of common stock and accompanying Series A and Series B warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a combined public offering price of $1.25, resulting in gross proceeds of approximately $5.0 million.
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering Read More »
The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® in combination with standard-of-care bortezomib, lenalidomide and dexamethasone met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma.
